Employer Coverage of GLP-1 Medications Faces New Scrutiny

𝗠𝗮𝗿𝗸𝗲𝘁 𝗦𝗶𝗴𝗻𝗮𝗹

Employer coverage for GLP-1 medications, such as Wegovy and Zepbound, is facing increased scrutiny as rising pharmacy costs pressure health plan budgets. In many conventional carrier-bundled arrangements, these therapies are purchased at or near list price, often exceeding $1,300 per member per month. As utilization continues to grow, some employers are responding by tightening eligibility requirements, increasing employee cost-sharing, or eliminating coverage altogether.

𝗛𝗣𝗫 𝗣𝗲𝗿𝘀𝗽𝗲𝗰𝘁𝗶𝘃𝗲

The debate surrounding GLP-1s is often framed as a choice between covering the drugs or cutting them from the plan.

That is the wrong question.

The more important question is how these therapies are being sourced. Large employers have increasingly moved away from traditional carrier-controlled pharmacy arrangements in favor of specialized PBMs and alternative procurement strategies that can significantly reduce the net cost of high-cost medications.

In many cases, employers can access the same brand-name GLP-1 therapies for $500 per month or less through a more efficient pharmacy supply chain.

The difference between a $1,500 drug and a $500 drug is not the medication itself. It is the purchasing strategy behind it.

𝗪𝗵𝘆 𝗜𝘁 𝗠𝗮𝘁𝘁𝗲𝗿𝘀

For many employers, GLP-1 medications are no longer a fringe benefit consideration. They are becoming a workforce issue.

A recent NFP survey found that nearly 30% of employees would consider changing jobs to gain access to GLP-1 coverage. At the same time, many employers are struggling to absorb the cost of broad coverage under conventional pharmacy arrangements.

Organizations that can balance affordability and access may gain a meaningful advantage in both employee satisfaction and talent retention.

𝗟𝗼𝗼𝗸𝗶𝗻𝗴 𝗔𝗵𝗲𝗮𝗱

The next phase of the GLP-1 conversation will likely shift away from whether these therapies should be covered and toward how they should be managed.

As utilization continues to rise, employers will increasingly evaluate specialized pharmacy strategies, alternative sourcing models, and unbundled benefit structures designed to improve pricing efficiency while preserving access.

The employers that succeed will not necessarily be those that spend the most on healthcare. They will be the ones that purchase it most intelligently.